Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (121-130 of 193) with videos related to

Pageof 20
Sort By:
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
The Journal of Rheumatology|March 16, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III StudiesGeorg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|July 5, 2017
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK studyMatthew A Brown, Paul A Bird, Philip C Robinson, et al.
Annals of the Rheumatic Diseases|November 27, 2013
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohortLiesbet Van Praet, Lennart Jans, Philippe Carron, et al.
Skeletal Radiology|September 8, 2023
Association of anatomical variants of the sacroiliac joint with bone marrow edema in patients with axial spondyloarthritisElke Vereecke, Lennart Jans, Nele Herregods, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Seminars in Arthritis and Rheumatism|July 30, 2022
Discriminative power of salivary gland ultrasound in relation to symptom-based endotypes in suspected and definite primary Sjögren's SyndromeLiselotte Deroo, Helena Achten, Kristel De Boeck, et al.
RMD Open|June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trialVictoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
RMD Open|November 30, 2018
Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of lifeMaike Imkamp, Valéria Lima Passos, Annelies Boonen, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Pageof 20

Showing results (121-130 of 193) with videos related to

Sort By:
Pageof 20
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
The Journal of Rheumatology|March 16, 2021
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III StudiesGeorg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|July 5, 2017
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK studyMatthew A Brown, Paul A Bird, Philip C Robinson, et al.
Annals of the Rheumatic Diseases|November 27, 2013
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohortLiesbet Van Praet, Lennart Jans, Philippe Carron, et al.
Skeletal Radiology|September 8, 2023
Association of anatomical variants of the sacroiliac joint with bone marrow edema in patients with axial spondyloarthritisElke Vereecke, Lennart Jans, Nele Herregods, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Seminars in Arthritis and Rheumatism|July 30, 2022
Discriminative power of salivary gland ultrasound in relation to symptom-based endotypes in suspected and definite primary Sjögren's SyndromeLiselotte Deroo, Helena Achten, Kristel De Boeck, et al.
RMD Open|June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trialVictoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
RMD Open|November 30, 2018
Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of lifeMaike Imkamp, Valéria Lima Passos, Annelies Boonen, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Pageof 20